Technical Analysis for DXCM - DexCom, Inc.

Grade Last Price % Change Price Change
B 400.04 0.14% 0.55
DXCM closed up 0.14 percent on Friday, April 16, 2021, on 72 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
Earnings due: Apr 26
*** please verify all earnings dates ***

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up
Historical DXCM trend table...

Date Alert Name Type % Chg
Pocket Pivot Bullish Swing Setup 0.00%
Doji - Bearish? Reversal 0.00%
Overbought Stochastic Strength 0.00%
Up 3 Days in a Row Strength 0.00%
Up 4 Days in a Row Strength 0.00%
Up 5 Days in a Row Strength 0.00%
New Uptrend Bullish 0.14%
Pocket Pivot Bullish Swing Setup 0.14%
Upper Bollinger Band Walk Strength 0.14%
Overbought Stochastic Strength 0.14%
Older End-of-Day Signals for DXCM ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


DexCom, Inc. Description

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring systems. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers in the hospital for the treatment of patients with and without diabetes. Its ambulatory product line includes SEVEN PLUS, DexCom G4 system, and DexCom G4 PLATINUM system for adults with diabetes to detect trends and track glucose patterns, to aid in the detection of hypoglycemia and hyperglycemia, and to facilitate acute and long-term therapy adjustments. The company's in-hospital product line comprises GlucoClear, a blood-based in-vivo automated glucose monitoring system for use by healthcare providers in the hospital. It also offers SweetSpot, a software platform that enables patients to aggregate and analyze data from diabetes devices and to share it with their healthcare providers. The company markets its products directly to endocrinologists, physicians, and diabetes educators primarily in the United States. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.


Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Medicine Diabetes Telemedicine Telehealth Healthcare Providers Software Platform Endocrine System Glucose Platinum Diabetes Mellitus Medical Monitoring Endocrinology Blood Glucose Monitoring Hypoglycemia Continuous Glucose Monitor Hyperglycemia Glucose Monitoring Systems

Is DXCM a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 456.23
52 Week Low 305.63
Average Volume 735,721
200-Day Moving Average 383.53
50-Day Moving Average 379.44
20-Day Moving Average 369.22
10-Day Moving Average 383.77
Average True Range 11.50
ADX 26.36
+DI 29.16
-DI 11.57
Chandelier Exit (Long, 3 ATRs ) 367.16
Chandelier Exit (Short, 3 ATRs ) 371.63
Upper Bollinger Band 403.61
Lower Bollinger Band 334.83
Percent B (%b) 0.95
BandWidth 18.63
MACD Line 7.36
MACD Signal Line 2.40
MACD Histogram 4.9642
Fundamentals Value
Market Cap 38.41 Billion
Num Shares 96 Million
EPS 2.42
Price-to-Earnings (P/E) Ratio 165.37
Price-to-Sales 18.14
Price-to-Book 22.07
PEG Ratio 2.64
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 412.06
Resistance 3 (R3) 411.26 406.45 410.05
Resistance 2 (R2) 406.45 403.39 406.85 409.38
Resistance 1 (R1) 403.25 401.50 400.85 404.05 408.72
Pivot Point 398.44 398.44 397.24 398.84 398.44
Support 1 (S1) 395.24 395.38 392.84 396.04 391.36
Support 2 (S2) 390.43 393.49 390.83 390.70
Support 3 (S3) 387.23 390.43 390.03
Support 4 (S4) 388.03